The Development of Prostate Adenocarcinoma in a Transgender Male to Female Patient: Could Estrogen Therapy Have Played a Role?
The Development of Prostate Adenocarcinoma in a Transgender Male to Female Patient: Could Estrogen Therapy Have Played a Role?
复制标题
跨性别男性变女性患者前列腺腺癌的发展：雌激素治疗是否发挥了作用？
DOI：
10.1002/pros.23322
复制
发表时间：
2017
期刊：
影响因子：
--
通讯作者：
Abern,MichaelR
中科院分区：
文献类型：
--
作者：
Sharif,Asma;Malhotra,NehaR;Acosta,AndresM;Kajdacsy-Balla,AndreA;Bosland,Maarten;Guzman,Grace;Prins,GailS;Abern,MichaelR
前列腺腺癌（PCa）是一种罕见的诊断在男性到女性的跨性别（MtFT）人群中，只有少数病例报告发表在当前的医学文献。雄激素抑制对前列腺癌发展具有保护作用的长期信念受到了文献的挑战，文献引用了啮齿动物模型在雌激素和睾酮联合治疗后前列腺腺癌的发展。材料和方法我们在此介绍了一名MtFT患者，他在20年的外源性雌激素治疗后出现了高级别的PCa。雌激素受体α（ER-α）和孕激素受体（PR）在间质细胞中表达阳性;同时，雄激素受体结论：这种染色模式引起了对外源性雌激素治疗在乳腺癌中可能起作用的关注。肿瘤发生随着对性别焦虑症的认识和对性别重置手术的接受程度最近有所增加，必须认识到这一人群的独特需求。前列腺77：824-828，2017。© 2017 Wiley Periodicals，Inc.
BACKGROUNDProstate adenocarcinoma (PCa) is a rare diagnosis in the male to female transgender (MtFT) population with only a few case reports published in the current medical literature. Long standing beliefs of androgen suppression conferring a protective effect against prostate cancer development have been challenged by the literature citing adenocarcinoma development in the prostate of rodent models following combined estrogen and testosterone treatment.MATERIALS AND METHODSWe herein present a MtFT patient who presented with high grade PCa following 20 years of exogenous estrogen therapy.RESULTSImmunohistochemical (IHC) localization of estrogen receptor alpha (ER‐α) and progesterone receptor (PR) demonstrated positive staining in stromal cells; while, androgen receptor (AR) demonstrated positive staining in malignant glands and weak scattered staining in adjacent stroma.CONCLUSIONThis pattern of staining raises concern for a possible contributing role of exogenous estrogen therapy in tumorigenesis. As awareness of gender dysphoria and acceptance of gender reassignment surgery has seen a recent increase, the unique needs of this population must be recognized.Prostate 77:824–828, 2017. © 2017 Wiley Periodicals, Inc.